Marketing-authorisation holder Β· Canada
Biogen Canada Inc
18 medicines in 1 country, as authorisation holder.
Loading your pageβ¦
Marketing-authorisation holder Β· Canada
18 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
18 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AVONEX30 mcg / 0.5 ml Β· Solution | Interferon beta-1a | Canada | Marketed | 2005 |
| AVONEX60 mcg / ml Β· Powder For Solution | Interferon beta-1a | Canada | Authorised | |
| PLEGRIDY63 mcg / 0.5 ml Β· Liquid | Peginterferon beta-1a | Canada | Authorised | |
| PLEGRIDY63 mcg / 0.5 ml + 94 mcg / 0.5 ml Β· Kit, Liquid | Peginterferon beta-1a | Canada | Marketed | 2015 |
| PLEGRIDY125 mcg / 0.5 ml Β· Liquid | Peginterferon beta-1a | Canada | Marketed | 2015 |
| PLEGRIDY94 mcg / 0.5 ml Β· Liquid | Peginterferon beta-1a | Canada | Authorised | |
| QALSODY100 mg / 15 ml Β· Solution | Tofersen | Canada | Marketed | 2025 |
| SKYCLARYS50 mg Β· Capsule | Omaveloxolone | Canada | Marketed | 2025 |
| SPINRAZA2.4 mg / ml Β· Solution | Nusinersen | Canada | Marketed | 2017 |
| TECFIDERA240 mg Β· Capsule (Delayed-Release) | Dimethyl | Canada | Marketed | 2014 |
| TECFIDERA120 mg Β· Capsule (Delayed-Release) | Dimethyl | Canada | Marketed | 2013 |
| TYSABRI300 mg / 15 ml Β· Solution | Natalizumab | Canada | Marketed | 2006 |
| ZURZUVAE30 mg Β· Capsule | Zuranolone | Canada | Authorised | |
| ZURZUVAE25 mg Β· Capsule | Zuranolone | Canada | Marketed | 2026 |
| ZURZUVAE20 mg Β· Capsule | Zuranolone | Canada | Marketed | 2026 |
| AVONEX30 mcg / kit + 1.1 ml / kit Β· Powder For Solution | Interferon beta-1a, Water | Canada | Cancelled | 1998 |
| ZINBRYTA150 mg / ml Β· Solution | Daclizumab | Canada | Cancelled | 2017 |
| ZINBRYTA150 mg / ml Β· Solution | Daclizumab | Canada | Cancelled |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 18 | 15 | 3 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.